12 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
27 Oct 23
Regulation FD Disclosure
4:19pm
complications include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity
DRS
EX-10.9
CHRS
Coherus Biosciences Inc
4 Aug 14
Draft registration statement
12:00am
by Lessee as a result of an actual or proposed change in use, change in intensity of use, or modification to the Premises then, and in that event, Lessee … shall either: (i) immediately cease such changed use or intensity of use and/or take such other steps as may be necessary to eliminate
424B4
CHRS
Coherus Biosciences Inc
6 Nov 14
Prospectus supplement with pricing info
12:00am
in subcutaneously injected drug may cause injection site reactions. We found these to be no more frequent or worse in intensity than those normally reported … for Enbrel (i.e., mild to moderate intensity and resolving without medical intervention over hours to days). We also reviewed the adverse events reported
10-K
2014 FY
CHRS
Coherus Biosciences Inc
23 Mar 15
Annual report
12:00am
injection site reactions. We found these to be no more frequent or worse in intensity than those normally reported for Enbrel (i.e., mild to moderate … intensity and resolving without medical intervention over hours to days). We also reviewed the adverse events reported in the ongoing clinical trials
- Prev
- 1
- Next